PTC Therapeutics (PTCT) Competitors $65.37 +2.35 (+3.73%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$65.35 -0.02 (-0.03%) As of 10/3/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTCT vs. GMAB, SMMT, RDY, ASND, VTRS, MRNA, ROIV, QGEN, BBIO, and ELANShould you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Moderna (MRNA), Roivant Sciences (ROIV), Qiagen (QGEN), BridgeBio Pharma (BBIO), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. PTC Therapeutics vs. Its Competitors Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Moderna Roivant Sciences Qiagen BridgeBio Pharma Elanco Animal Health PTC Therapeutics (NASDAQ:PTCT) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk. Do analysts rate PTCT or GMAB? PTC Therapeutics currently has a consensus price target of $69.00, indicating a potential upside of 5.55%. Genmab A/S has a consensus price target of $40.80, indicating a potential upside of 21.57%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts clearly believe Genmab A/S is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50Genmab A/S 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.67 Which has better valuation and earnings, PTCT or GMAB? Genmab A/S has higher revenue and earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$1.76B2.94-$363.30M$6.979.38Genmab A/S$3.12B6.90$1.14B$1.9916.86 Do institutionals and insiders have more ownership in PTCT or GMAB? 7.1% of Genmab A/S shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to PTCT or GMAB? In the previous week, Genmab A/S had 21 more articles in the media than PTC Therapeutics. MarketBeat recorded 25 mentions for Genmab A/S and 4 mentions for PTC Therapeutics. Genmab A/S's average media sentiment score of 0.56 beat PTC Therapeutics' score of 0.40 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 5 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, PTCT or GMAB? PTC Therapeutics has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Is PTCT or GMAB more profitable? Genmab A/S has a net margin of 37.53% compared to PTC Therapeutics' net margin of 35.65%. Genmab A/S's return on equity of 21.03% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Genmab A/S 37.53%21.03%16.98% SummaryGenmab A/S beats PTC Therapeutics on 13 of the 17 factors compared between the two stocks. Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTCT vs. The Competition Export to ExcelMetricPTC TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.01B$3.31B$6.04B$10.58BDividend YieldN/A2.27%5.68%4.69%P/E Ratio9.3821.7377.3326.67Price / Sales2.94447.05602.54132.27Price / CashN/A46.6137.7361.25Price / Book-4.599.9312.556.55Net Income-$363.30M-$52.59M$3.30B$277.26M7 Day Performance10.82%5.22%28,056.12%2.37%1 Month Performance12.69%13.01%28,993.64%9.30%1 Year Performance86.24%25.19%35,460.83%30.78% PTC Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTCTPTC Therapeutics3.4259 of 5 stars$65.37+3.7%$69.00+5.6%+84.8%$5.01B$1.76B9.381,410High Trading VolumeGMABGenmab A/S4.0979 of 5 stars$28.60+1.1%$39.25+37.2%+43.4%$18.35B$3.26B14.372,682Trending NewsAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics3.0048 of 5 stars$19.10+1.1%$31.87+66.8%+15.2%$14.19B$700K-18.91110RDYDr. Reddy's Laboratories3.2691 of 5 stars$14.59-1.9%$16.95+16.2%-11.0%$12.18B$3.81B22.1127,811Positive NewsASNDAscendis Pharma A/S3.282 of 5 stars$196.42-0.6%$244.36+24.4%+44.8%$12.10B$393.54M-38.071,017High Trading VolumeVTRSViatris1.2702 of 5 stars$9.79-1.1%$10.40+6.2%-10.8%$11.41B$14.12B-3.3832,000MRNAModerna4.2493 of 5 stars$26.56+5.2%$41.81+57.4%-53.3%$10.33B$3.06B-3.535,800Options VolumeROIVRoivant Sciences3.6464 of 5 stars$14.94-0.7%$19.94+33.5%+44.2%$10.20B$29.05M-21.34860QGENQiagen4.3614 of 5 stars$45.72-0.5%$49.69+8.7%+10.6%$10.16B$2.04B27.015,765Positive NewsAnalyst ForecastBBIOBridgeBio Pharma4.3611 of 5 stars$51.54-1.6%$63.94+24.1%+106.2%$9.85B$235.81M-12.60400ELANElanco Animal Health2.6406 of 5 stars$19.08-0.6%$17.33-9.2%+42.4%$9.48B$4.48B22.199,000News CoveragePositive News Related Companies and Tools Related Companies GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives MRNA Alternatives ROIV Alternatives QGEN Alternatives BBIO Alternatives ELAN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTCT) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredAmerica’s Lost StocksPorter Stansberry says the real fortunes aren’t in Tesla, Amazon, or AI — but in a handful of overlooked “lost...Porter & Company | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredBillionaire investor gives blunt market adviceThe Best Case for Gold, Ever Gold has hit all-time highs, breaking $3,600 an ounce - but history shows it c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts